Double-Drug attack shows promise against tough head and neck cancers
NCT ID NCT03370276
First seen Oct 31, 2025 · Last updated May 24, 2026 · Updated 24 times
Summary
This study tested whether combining two approved cancer drugs, cetuximab and nivolumab, could help people with advanced head and neck cancer that had returned or spread. A total of 95 participants received the combination to see if it improved survival and shrank tumors. The goal was to find a better treatment option for this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Emory University School of Medicine
Atlanta, Georgia, 30322, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
The Ohio State University
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.